OncoMatch/Clinical Trials/NCT07246564
Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia Gravis
Is NCT07246564 recruiting? Yes, currently enrolling (Jun 2026). This Phase 4 trial studies Rozanolixizumab for myasthenia gravis.
Treatment: Rozanolixizumab — The purpose of the study is to assess the clinical efficacy of rozanolixizumab in adult Chinese participants with generalized myasthenia gravis (gMG) in the first Treatment Cycle.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Disease stage
Required: Stage MGFA II, MGFA III, MGFA IV (MGFA Clinical Classification)
Myasthenia Gravis Foundation of America (MGFA) Clinical Classification II to IV at Screening Visit
Prior therapy
Cannot have received: anti-neonatal Fc receptor medication (rozanolixizumab)
previously received rozanolixizumab drug product
Cannot have received: immunosuppressants, biologics, and other therapies
treated with prohibited immunosuppressants, biologics, and other therapies within the timeframe shorter than the treatment-free period
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07246564 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior anti-neonatal Fc receptor medication, immunosuppressants, biologics, and other therapies disqualifies patients from enrollment.
What disease stage is eligible?
Stage MGFA II or MGFA III or MGFA IV is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify